Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biora Therapeutics, Inc. - Common Stock (NQ: BIOR )

0.6481 +0.0039 (+0.61%)
Streaming Delayed Price Updated: 3:47 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biora Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Biora Therapeutics Achieves ISO 13485 Certification
Underscoring the company’s commitment to quality and excellence 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Positive Nasdaq Listing Decision
Company granted extension to regain compliance with Nasdaq listing requirements 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Funding Agreement with Existing Investors
$16 million multiple-draw facility to be used as a bridge to anticipated pharma partnership 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
Four clinical device performance studies successfully demonstrate the NaviCap platform’s ability to deliver therapeutics directly to the colon under variable GI conditions and eating schedules 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
Claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal tract 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Provides Outlook for 2024
Multiple catalysts anticipated in 2024, including clinical study results for NaviCap™ Targeted Oral Delivery Platform and progress on pharma partnerships for BioJet™ Systemic Oral Delivery Platform 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
BioJet device exceeded performance targets for delivery of collaborator AstraZeneca’s molecule in preclinical study 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform
Patent addresses targeted delivery of JAK inhibitors to the gastrointestinal tract 
From Biora Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.